Stockreport

Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients [Yahoo! Finance]

Stoke Therapeutics, Inc.  (STOK) 
Last stoke therapeutics, inc. earnings: 11/12 08:00 am Check Earnings Report
PDF of children and adolescents ages 2 to 18 with Dravet syndrome who were treated with STK-001 Dravet syndrome is a severe and progressive genetic epilepsy characterized [Read more]